Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06720610

Indonesian Study of Vonoprazan Vs Esomeprazole in Erosive Esophagitis

The goal of this clinical trial is to compare drug vonoprazan vs esomeprazole effectiveness to relieve early symptoms in Erosive Esophagitis Patients. It will also learn about the safety of both modalities. The main questions it aims to answer are:

How does the effectiveness of Vonoprazan compare with Esomeprazole in improving early symptoms of erosive esophagitis patients in the Indonesian population?

Researchers will compare drug vonoprazan to a esomeprazole with a look-alike packaging to see their effect to reduce early symptoms of erosive esophagitis.

Participants will:

* Take drug vonoprazan 20mg or esomeprazole 40mg one time every day for 2 weeks * Visit the clinic once every weeks for followup (Gastro Esophageal Reflux Disease-Quetionnaire measurement) * Keep a diary of their adverse effect occurence and every variable data based on Gastro Esophageal Reflux Disease-Questionnaire.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Hermina Jatinegara Hospital, East Jakarta, DKI Jakarta, Indonesia

Loading trial locations.

About this study

Based on the calculation using the formula for comparing two population proportions, the minimum estimated sample size is 97 samples for each group. Considering a potential 10% drop-out rate, the estimated sample size increases to 108 samples per group. Therefore, the total minimum sample required for this study is 216 samples for both groups.

All the patients will screened using the Gastro Esophageal Reflux Disease-Quetionnaire (6 questions, 4 answer options, covering the last 7 days) and collected through RedCap. After that all eligible patients will undergo endoscopic examination that performed by gastroenterology specialists or trained internists.

Included patients who consume any Proton Pump Inhibiotr or Potassium-competitive acid blockers within 2 weeks prior to this study will undergo wash-out period for 2 weeks. Patients are monitored weekly during the wash-out period. Medication reminders are sent via instant messaging at least twice per week. Adverse Event will be monitored by research assistants in coordination with the patient's primary physician.

All the data will analyzed blindly with Chi-square or Fisher's exact test for categorical data and logistic regression for confounding factors. At the end of the study, the pharmacy team will reveal the group allocation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged >18 years with a GERD-Q score of 8.
  • Diagnosed with erosive esophagitis by endoscopy. (Los Angeles Classification A-D)
  • Patients are willing to undergo a series of therapeutic management.

Exclusion criteria

  • Patients with a history of allergy to PCAB or PPI groups.
  • Patients with gastric and/or duodenal ulcers.
  • Patients with Helicobacter pylori infection.
  • Patients with a history of significant systemic disease disorders affecting the esophagus and stomach.
  • Patients with a history of malignant disease related to the esophagus and/or stomach.
  • Patients with a history of esophageal and/or gastric surgery.
  • Pregnant patients

Treatment and study plan

Vonoprazan 20 mg

Drug

Vonoprazan PO, 20mg, once a day, 14 days.

Other names: vocinti

Esomeprazole

Drug

Esomeprazole PO, 40mg, once a day, 14 days

Other names: Esomeprazole generic

Primary outcomes

  1. Number of Participants with Symptoms Resolution of Erosive Esophagitis

    Time frame: 14 days (two weeks)

    Participants achieved a,

    • complete resolution if they scored a GERD-Q questionnaire of 0 from scale 0-18. - sufficient relief if they scored GERD-Q of 1 or 0 (No. 1,2,5,6)
    • persistent response if they score GERD-Q of 2 or more in any single question.

Secondary outcomes

  1. Number of Participants with Adverse Event

    Time frame: 14 days (two weeks)

    Yes: nasopharyngitis, diarrhea, acute upper respiratory infection, lower back pain, constipation No: none of any

Other outcomes

  1. Rate of Drug Compliance

    Time frame: 14 days (two weeks)

    Compliant (14 drugs finished in 14 days) Lack of compliance (14 drugs finished in >14 days) Non-compliant (not taking drugs)

Study contacts

Contact information is provided by the study sponsor or research team.

Ari F Syam, MD

CONTACT

[email protected]

+62818706199

Ryan Herardi, MD

CONTACT

[email protected]

+6281381166910

Sponsors and collaborators

Lead sponsor

Indonesia University

Other

Registry information

Official study title

Comparison of the Effectiveness of Vonoprazan and Esomeprazole in Improving Initial Symptoms in Patients with Erosive Esophagitis: a Double-Blind Randomized Trial

Acronym: INVEST

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Dec 6, 2024
Registry last updated
Dec 17, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.